effect overlay
activetrials

58-Week Open-Label Trial of Tavapadon in Parkinson’s Disease
 

HREC: 2020.310
Principal Investigator: Dr Andrew Evans
Coordinator contact: Fiona Leen
Funding: Commercial
Movement Disorders

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy
 

HREC: 2020.317
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Non-Commercial
Movement Disorders

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
 

HREC: 2023.188
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Commercial
Movement Disorders

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson's Disease
 

HREC: 2024.061
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Non-Commercial